The ideal audience for this transcript includes Dermatopathologists, Soft Tissue Pathologists, and Surgical Pathology Residents/Fellows. The material serves as a high-value clinical correlation study on "anchoring bias" in diagnostics and the emerging category of kinase-fused mesenchymal tumors.
This clinical case review details the diagnostic workup of a slow-growing, reddish plaque on the leg of a 23-year-old female. Morphologically, the lesion exhibited a deceptive vascular-like growth pattern, initially leading to a differential of microvenular hemangioma. Histological examination revealed a bland spindle cell proliferation infiltrating the subcutaneous fat. Immunohistochemical (IHC) profiling demonstrated co-expression of CD34 and S100, but a negative result for SOX10.
The diagnostic breakthrough occurred by identifying the "anchoring bias" associated with the prominent vascular network and pivoting toward molecular analysis. Next-Generation Sequencing (NGS) confirmed an NTRK3 fusion, reclassifying the lesion as an NTRK-rearranged mesenchymal neoplasm. The discussion emphasizes the importance of recognizing the "monotonous" cellular morphology characteristic of fusion-associated tumors and the limitations of Pan-TRK IHC compared to molecular confirmation.
Case Analysis: NTRK-Rearranged Mesenchymal Neoplasm
00:03 Clinical Presentation: A 23-year-old female presented with a slowly growing, reddish-violaceous plaque on the leg, present for several years.
01:07 Histomorphology: The lesion is highly infiltrative, extending deep into the subcutaneous tissue and "trickling" through collagen bundles and adipocytes. Nuclei appear bland and "bubbly" rather than overtly malignant.
02:15 Initial IHC (Vascular Markers): Strong positivity for CD34 and CD31. The "thin, compressed dermal vessels" initially suggested a primary vascular process.
03:46 Secondary IHC (Neural Markers): S100 protein showed significant positivity with a dendritic cell morphology. Crucially, the tumor was negative for SOX10, an unusual profile for traditional neural tumors.
05:50 The Pitfall of Anchoring Bias: The presenters discuss the initial error of misclassifying the lesion as a "weird microvenular hemangioma." The prominence of the vascular network masked the underlying spindle cell neoplasm.
08:13 Diagnostic Philosophy: A key takeaway is the "Rule of Naming": If a tumor looks cytologically benign but lacks a specific name/box, it requires expert consultation or molecular workup to exclude "pattern-based" malignancies like DFSP or translocation sarcomas.
10:27 Molecular Red Flags: The specific IHC combination of CD34(+), S100(+), and SOX10(-) is identified as a high-sensitivity signature for NTRK-rearranged neoplasms.
12:23 Molecular Confirmation: Next-Generation Sequencing (NGS) identified an NTRK3 fusion. This places the tumor in an emerging class of kinase-fused neoplasms that range from indolent to aggressive based on cytologic features.
14:48 Pan-TRK IHC vs. NGS: Discussion on the Pan-TRK surrogate marker; while useful for screening, it lacks perfect sensitivity/specificity and often requires molecular follow-up to identify the specific fusion partner.
15:28 Morphological Clue (Monotony): A critical diagnostic pearl: "Cellular monotony" in a spindle cell lesion is frequently a hallmark of fusion-associated neoplasms in soft tissue pathology.